

Cipla Launches India's First Dedicated Lung Health Diagnostics Center in Delhi

- *Celebrating 90 years of healthcare innovation at Cipla, this integrated lung health center will introduce specialised respiratory diagnostics in India*
- *Providing a comprehensive gamut of over 60 tests covering lung physiology, microbiology, immunology, blood chemistry and radiology*

Mumbai & New Delhi, November 28, 2025: Cipla Limited (BSE: 500087; NSE: CIPLA; and hereafter referred to as "Cipla") today announced the launch of Cipla's first Breathefree Lung Wellness Center in Lajpat Nagar in New Delhi. This will be India's first-of-its-kind integrated lung diagnostics and wellness center, set to redefine respiratory care by making world-class, advanced standardised lung diagnostics both accessible and affordable for doctors and patients across the country.

Respiratory diseases have been on the rise in India, with millions remaining undiagnosed or misdiagnosed due to limited access to advanced pulmonary function testing and comprehensive diagnostic infrastructure in the respiratory domain. The Breathefree Lung Wellness Center is designed to be a one-stop solution for comprehensive lung health diagnostics, leveraging Cipla's decades of expertise and commitment to respiratory diseases and health. The center brings together cutting-edge technology, globally recognised diagnostic protocols, and a team of highly trained technical professionals who perform tests with precision, enabling doctors to detect respiratory diseases early and accurately.

The center will provide a comprehensive gamut of over 60 tests covering lung physiology, microbiology, immunology, blood chemistry and radiology. The aim is to enable a more comprehensive evaluation of the lungs for patients suspected of having a respiratory disease or those already diagnosed with a lung condition - ranging from common diseases like Asthma and COPD to more complex ones such as interstitial lung diseases (ILD). Tests include Spirometry, Oscillometry, FeNO, DLCO, Body Plethysmography, F_nNO, CPET, X-Ray and CT scan, sleep studies, etc. which will be conducted by highly trained technicians to eliminate errors and inconsistencies. In addition, the center will also provide pulmonary nutrition and rehabilitation services, and counselling for smoking cessation to aid patients on their rehabilitation journeys. The center is now open and

currently welcoming patients through referrals from clinicians, offering the highest standards in respiratory diagnostics and care.

Commenting on this milestone, Mr. Achin Gupta, Global Chief Operating Officer, Cipla Limited, said, *“Cipla has long been a pioneer in respiratory care, and with the launch of the first Breathefree Lung Wellness Center, we are addressing a critical gap in the diagnostic landscape. By expanding our presence across the care continuum, we are aiming to transform lung health diagnostics in India by making high-quality, standardised lung diagnostics accessible to healthcare professionals and patients, ultimately improving respiratory health outcomes.”*

Dr. Jaideep Gogtay, Global Chief Medical Officer, Cipla Limited, added, *“India is estimated to have over 90 million people with chronic respiratory diseases. Early and accurate diagnosis is crucial for physicians to initiate appropriate treatment for their patients, reduce the risk for hospitalization and improve the quality of life. Cipla has always recognised the need to address this burden, and the launch of this center is a natural extension of our lung leadership efforts. Through this initiative, we aim to transform lung health diagnostics in India by strengthening the foundation of respiratory care.”*

Beyond being a holistic lung wellness center, it aims to become an extensive training center for health care professionals on the latest diagnostic methodologies and get them certified. There will also be opportunities for conducting research to advance respiratory science.

About Cipla

Established in 1935, Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening portfolio in our home markets of India, South Africa, North America, and key regulated and emerging markets. Our strengths in the respiratory, anti-retroviral, urology, cardiology, anti-infective and CNS segments are well-known. Our 46 manufacturing sites around the world produce 50+ dosage forms and 1,500+ products using cutting-edge technology platforms to cater to our 80+ markets. Cipla is ranked 3rd largest in pharma in India (IQVIA MAT Sep'25), 2nd

Largest in the pharma prescription market in South Africa (IQVIA MAT Aug'25), and 4th largest by prescription in the US Gx (Repulses + MDI) products (IQVIA MAT Aug'25). For over eight decades, making a difference to patients has inspired every aspect of Cipla's work. Our paradigm-changing offer of a triple anti-retroviral therapy in HIV/AIDS at less than a dollar a day in Africa in 2001 is widely acknowledged as having contributed to bringing inclusiveness, accessibility and affordability to the centre of the HIV movement. A responsible corporate citizen, Cipla's humanitarian approach to healthcare in pursuit of its purpose of 'Caring for Life' and deep-rooted community links wherever it is present make it a partner of choice to global health bodies, peers and all stakeholders. For more, please visit www.cipla.com, or click on [Twitter](#), [Facebook](#), [LinkedIn](#).

Media Contacts:**Corporate Communications**

Heena Kanal

E-Mail: CorpComm@cipla.com

Investor Relations

Diksha Maheshwari

E-Mail: Investor.Relations@cipla.com